Birch Allergy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major birch allergy markets reached a value of US$ 399.2 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 710.1 Million by 2034, exhibiting a growth rate (CAGR) of 5.38% during 2024-2034.
The birch allergy market has been comprehensively analyzed in IMARC's new report titled "Birch Allergy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Birch allergy is a common type of seasonal disease triggered by an individual's immune response to proteins found in birch tree pollen. Birch trees are prevalent in many regions, particularly in temperate climates, and their pollen becomes airborne during springtime, leading to allergic reactions in sensitive people. The symptoms of the ailment can range from mild to severe and typically manifest in the respiratory system and skin. Some common symptoms include sneezing, a runny or stuffy nose, itchy and watery eyes, nasal congestion, and throat irritation. In a few cases, individuals suffering from this illness may also experience skin rashes, hives, or eczema. Diagnosing a birch allergy involves a comprehensive evaluation by an allergist. The process often begins with a thorough medical history and a physical examination to assess the symptoms and potential triggers. Allergy testing, like skin prick tests or blood workups, is also recommended to identify the specific allergens responsible for the disease.
The increasing prevalence of various environmental factors, including climate change and poor air quality, which lead to extended pollen seasons and higher pollen concentrations, is primarily driving the birch allergy market. In addition to this, the rising incidence of inadequate or lack of immunization against specific allergens, resulting in an enhanced risk of developing allergic reactions, is also creating a positive outlook for the market. Moreover, the widespread adoption of effective drugs, such as antihistamines, corticosteroids, leukotriene modifiers, etc., to manage the symptoms of the ailment by blocking the release or effects of histamines, inflammatory molecules, and leukotrienes, respectively, is further bolstering the market growth. Additionally, the rising usage of allergen immunotherapy, including subcutaneous and sublingual treatments, is also acting as another significant growth-inducing factor. This therapy works by gradually exposing patients to small amounts of the allergen, such as birch pollen, to desensitize their immune system and reduce the severity of allergic reactions over time. Furthermore, the emerging popularity of epinephrine auto-injectors, since they help to counteract the effects of allergens, restore normal breathing and heart rate, and provide immediate relief in severe disease conditions like anaphylaxis, is expected to drive the birch allergy market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the birch allergy market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for birch allergy and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the birch allergy market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the birch allergy market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the birch allergy market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current birch allergy marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
How has the birch allergy market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the birch allergy market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the birch allergy market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of birch allergy across the seven major markets?
What is the number of prevalent cases (2018-2034) of birch allergy by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of birch allergy by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with birch allergy across the seven major markets?
What is the size of the birch allergy patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of birch allergy?
What will be the growth rate of patients across the seven major markets?
Birch Allergy: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for birch allergy drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the birch allergy market?
What are the key regulatory events related to the birch allergy market?
What is the structure of clinical trial landscape by status related to the birch allergy market?
What is the structure of clinical trial landscape by phase related to the birch allergy market?
What is the structure of clinical trial landscape by route of administration related to the birch allergy market?
The birch allergy market has been comprehensively analyzed in IMARC's new report titled "Birch Allergy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Birch allergy is a common type of seasonal disease triggered by an individual's immune response to proteins found in birch tree pollen. Birch trees are prevalent in many regions, particularly in temperate climates, and their pollen becomes airborne during springtime, leading to allergic reactions in sensitive people. The symptoms of the ailment can range from mild to severe and typically manifest in the respiratory system and skin. Some common symptoms include sneezing, a runny or stuffy nose, itchy and watery eyes, nasal congestion, and throat irritation. In a few cases, individuals suffering from this illness may also experience skin rashes, hives, or eczema. Diagnosing a birch allergy involves a comprehensive evaluation by an allergist. The process often begins with a thorough medical history and a physical examination to assess the symptoms and potential triggers. Allergy testing, like skin prick tests or blood workups, is also recommended to identify the specific allergens responsible for the disease.
The increasing prevalence of various environmental factors, including climate change and poor air quality, which lead to extended pollen seasons and higher pollen concentrations, is primarily driving the birch allergy market. In addition to this, the rising incidence of inadequate or lack of immunization against specific allergens, resulting in an enhanced risk of developing allergic reactions, is also creating a positive outlook for the market. Moreover, the widespread adoption of effective drugs, such as antihistamines, corticosteroids, leukotriene modifiers, etc., to manage the symptoms of the ailment by blocking the release or effects of histamines, inflammatory molecules, and leukotrienes, respectively, is further bolstering the market growth. Additionally, the rising usage of allergen immunotherapy, including subcutaneous and sublingual treatments, is also acting as another significant growth-inducing factor. This therapy works by gradually exposing patients to small amounts of the allergen, such as birch pollen, to desensitize their immune system and reduce the severity of allergic reactions over time. Furthermore, the emerging popularity of epinephrine auto-injectors, since they help to counteract the effects of allergens, restore normal breathing and heart rate, and provide immediate relief in severe disease conditions like anaphylaxis, is expected to drive the birch allergy market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the birch allergy market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for birch allergy and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the birch allergy market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the birch allergy market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the birch allergy market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current birch allergy marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
How has the birch allergy market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the birch allergy market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the birch allergy market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of birch allergy across the seven major markets?
What is the number of prevalent cases (2018-2034) of birch allergy by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of birch allergy by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with birch allergy across the seven major markets?
What is the size of the birch allergy patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of birch allergy?
What will be the growth rate of patients across the seven major markets?
Birch Allergy: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for birch allergy drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the birch allergy market?
What are the key regulatory events related to the birch allergy market?
What is the structure of clinical trial landscape by status related to the birch allergy market?
What is the structure of clinical trial landscape by phase related to the birch allergy market?
What is the structure of clinical trial landscape by route of administration related to the birch allergy market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 BIRCH ALLERGY - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 BIRCH ALLERGY - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 BIRCH ALLERGY - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 BIRCH ALLERGY - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 BIRCH ALLERGY - UNMET NEEDS
10 BIRCH ALLERGY - KEY ENDPOINTS OF TREATMENT
11 BIRCH ALLERGY - MARKETED PRODUCTS
11.1 List of Birch Allergy Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 BIRCH ALLERGY - PIPELINE DRUGS
12.1 List of Birch Allergy Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. BIRCH ALLERGY - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. BIRCH ALLERGY – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 BIRCH ALLERGY - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Birch Allergy - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Birch Allergy - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Birch Allergy - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Birch Allergy - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Birch Allergy - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Birch Allergy - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Birch Allergy - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Birch Allergy - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Birch Allergy - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Birch Allergy - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Birch Allergy - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Birch Allergy - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Birch Allergy - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Birch Allergy - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Birch Allergy - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Birch Allergy - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Birch Allergy - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Birch Allergy - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Birch Allergy - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Birch Allergy - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Birch Allergy - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Birch Allergy - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Birch Allergy - Access and Reimbursement Overview
16 BIRCH ALLERGY - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 BIRCH ALLERGY MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 BIRCH ALLERGY MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 BIRCH ALLERGY - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 BIRCH ALLERGY - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 BIRCH ALLERGY - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 BIRCH ALLERGY - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 BIRCH ALLERGY - UNMET NEEDS
10 BIRCH ALLERGY - KEY ENDPOINTS OF TREATMENT
11 BIRCH ALLERGY - MARKETED PRODUCTS
11.1 List of Birch Allergy Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 BIRCH ALLERGY - PIPELINE DRUGS
12.1 List of Birch Allergy Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. BIRCH ALLERGY - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. BIRCH ALLERGY – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 BIRCH ALLERGY - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Birch Allergy - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Birch Allergy - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Birch Allergy - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Birch Allergy - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Birch Allergy - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Birch Allergy - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Birch Allergy - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Birch Allergy - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Birch Allergy - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Birch Allergy - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Birch Allergy - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Birch Allergy - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Birch Allergy - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Birch Allergy - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Birch Allergy - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Birch Allergy - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Birch Allergy - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Birch Allergy - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Birch Allergy - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Birch Allergy - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Birch Allergy - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Birch Allergy - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Birch Allergy - Access and Reimbursement Overview
16 BIRCH ALLERGY - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 BIRCH ALLERGY MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 BIRCH ALLERGY MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
